BioCentury
ARTICLE | Clinical News

Genentech reports Phase III data for Hemlibra without inhibitors

May 25, 2018 3:30 PM UTC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported full data from the Phase III HAVEN 3 trial of Hemlibra emicizumab-kxwh as prophylaxis in hemophilia A patients without Factor VIII inhibitors. Data were presented at the World Federation of Hemophilia meeting in Glasgow.

Hemlibra is approved in the U.S., Europe and Japan for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with Factor VIII inhibitors. The drug is a bispecific mAb that binds Factor IXa and Factor X (FX)...